Izalontamab brengitecan

DB22567InvestigationalProtein Based Therapies

Izalontamab brengitecan is under investigation in clinical trial NCT07054567 (A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer).

Mechanism: Pharmacologically active on Epidermal growth factor receptor and Receptor tyrosine-protein kinase erbB-3
Curator reviewed
Also known as: iza-bren
Code names: BL-B01D1 · BMS-986507

Resolves to

Compound

UNIIUC2FX6YY3P

Targets

P00533EGFRP21860ERBB3

What you can answer from here — as of July 16, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

53Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Izalontamab brengitecan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account